ERBB2 and breast carcinoma: Besides, bi-steric mTORi RMC-6272-mediated inhibition of mTORC1 in ER + /HER2- breast cancer has displayed significant efficacy in hormone therapy-resistant acquired patient-derived xenografts, and in patient-derived xenografts from CDK4/6 inhibitor-resistant patients [328].